IN2014CN00989A - - Google Patents

Info

Publication number
IN2014CN00989A
IN2014CN00989A IN989CHN2014A IN2014CN00989A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A IN 989CHN2014 A IN989CHN2014 A IN 989CHN2014A IN 2014CN00989 A IN2014CN00989 A IN 2014CN00989A
Authority
IN
India
Prior art keywords
compounds
treprostinil
pah
prodrugs
covalent
Prior art date
Application number
Inventor
Ulrich Hersel
Harald Rau
Torben Lessmann
Nicola Bisek
Guillaume Maitro
Kennett Sprogøe
Thomas Wegge
Oliver Keil
Joachim Zettler
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of IN2014CN00989A publication Critical patent/IN2014CN00989A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/641—Branched, dendritic or hypercomb peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

The present invention relates to prodrugs or a pharmaceutically acceptable salt thereof comprising a covalent treprostinil carrier conjugate as well as pharmaceutical composition comprising said compounds. The compounds may be used as medicaments especially for diseases or disorders which can be treated by treprostinil such as pulmonary arterial hypertension (PAH).
IN989CHN2014 2011-08-12 2012-08-10 IN2014CN00989A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP11177409 2011-08-12
EP11195615 2011-12-23
EP12165508 2012-04-25
PCT/EP2012/065745 WO2013024052A1 (en) 2011-08-12 2012-08-10 Carrier-linked treprostinil prodrugs

Publications (1)

Publication Number Publication Date
IN2014CN00989A true IN2014CN00989A (en) 2015-04-10

Family

ID=46690494

Family Applications (1)

Application Number Title Priority Date Filing Date
IN989CHN2014 IN2014CN00989A (en) 2011-08-12 2012-08-10

Country Status (14)

Country Link
US (2) US9561287B2 (en)
EP (1) EP2741781A1 (en)
JP (1) JP6092867B2 (en)
KR (1) KR101997939B1 (en)
CN (1) CN103857413A (en)
AU (1) AU2012296954B2 (en)
BR (1) BR112014003225A2 (en)
CA (1) CA2843883C (en)
HK (1) HK1198359A1 (en)
IL (1) IL230712A (en)
IN (1) IN2014CN00989A (en)
MX (1) MX349950B (en)
WO (1) WO2013024052A1 (en)
ZA (1) ZA201400977B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6092867B2 (en) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス Carrier-linked treprostinil prodrug
WO2013160340A1 (en) * 2012-04-25 2013-10-31 Ascendis Pharma A/S Prodrugs of hydroxyl-comprising drugs
WO2014086961A1 (en) 2012-12-07 2014-06-12 Ascendis Pharma A/S Carrier-linked prostanoid prodrugs
WO2014110491A1 (en) 2013-01-11 2014-07-17 Theratrophix Llc Prodrugs of treprostinil
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CA2908244C (en) 2013-03-25 2021-04-20 United Therapeutics Corporation Process of making prostacyclin compounds with linker thiol and pegylated forms
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
KR102427785B1 (en) 2013-10-25 2022-07-29 인스메드 인코포레이티드 Prostacylin compounds, compositions and methods of use thereof
TWI685348B (en) * 2014-05-08 2020-02-21 美國禮來大藥廠 Rapid-acting insulin compositions
AU2015274377B2 (en) * 2014-06-13 2020-07-23 United Therapeutics Corporation Treprostinil formulations
EP3169660A1 (en) * 2014-07-16 2017-05-24 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
CA2967385C (en) 2014-11-18 2023-05-16 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
TWI540121B (en) 2014-12-01 2016-07-01 臺灣永光化學工業股份有限公司 Method and novel intermediate for preparing treprostinil diethanolamine
EP3226838A1 (en) * 2014-12-03 2017-10-11 Steadymed Ltd. Preservative-free treprostinil formulations and methods and devices for use with same
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
NZ743488A (en) 2016-01-08 2023-02-24 Ascendis Pharma Growth Disorders As Controlled-release cnp agonists with low initial npr-b activity
US11389511B2 (en) 2016-01-08 2022-07-19 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with reduced side-effects
US11311604B2 (en) 2016-01-08 2022-04-26 Ascendis Pharma Growth Disorders A/S Controlled-release CNP agonists with low NPR-C binding
JP7076371B2 (en) 2016-01-08 2022-05-27 アセンディス ファーマ グロース ディスオーダーズ エー／エス Sustained-release CNP agonist with increased NEP stability
EP3400020A1 (en) 2016-01-08 2018-11-14 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with large carrier moieties
HRP20221339T1 (en) 2016-01-08 2023-01-06 Ascendis Pharma Growth Disorders A/S Cnp prodrugs with carrier attachment at the ring moiety
MX2018009938A (en) 2016-03-01 2019-03-14 Ascendis Pharma Bone Diseases As Pth prodrugs.
US11896671B2 (en) 2016-07-13 2024-02-13 Ascendis Pharma A/S Conjugation method for carrier-linked prodrugs
JP2019529408A (en) 2016-09-15 2019-10-17 カムルス エービー Prostacyclin analog preparation
RS64203B1 (en) 2016-09-29 2023-06-30 Ascendis Pharma Growth Disorders As Combination therapy with controlled-release cnp agonists
KR102611820B1 (en) 2016-09-29 2023-12-07 아센디스 파마 본 디지즈 에이/에스 PTH compounds with low peak-to-trough ratios
BR112019005533A2 (en) 2016-09-29 2019-06-18 Ascendis Pharma Bone Diseases As dosing regimen for a controlled release pth compound
JP7039574B2 (en) 2016-09-29 2022-03-22 アセンディス ファーマ ボーン ディジージズ エー／エス Release control PTH compound escalating dose setting
EP3498283A1 (en) 2017-12-14 2019-06-19 Ipsol AG Glycosidic derivatives of treprostinil
MX2020012179A (en) 2018-05-18 2021-01-29 Ascendis Pharma Bone Diseases As Starting dose of pth conjugates.
WO2020064844A1 (en) 2018-09-26 2020-04-02 Ascendis Pharma A/S Treatment of infections
JP7383703B2 (en) 2018-09-26 2023-11-20 アセンディス ファーマ エー／エス Novel hydrogel conjugate
SG11202101982RA (en) 2018-09-26 2021-03-30 Ascendis Pharma As Degradable hyaluronic acid hydrogels
EP3906065A1 (en) 2019-01-04 2021-11-10 Ascendis Pharma Oncology Division A/S Minimization of systemic inflammation
WO2020141223A1 (en) 2019-01-04 2020-07-09 Ascendis Pharma A/S Induction of sustained local inflammation
MX2021007706A (en) 2019-01-04 2021-08-05 Ascendis Pharma Oncology Div A/S Conjugates of pattern recognition receptor agonists.
CN113316452A (en) 2019-01-04 2021-08-27 阿森迪斯药物肿瘤股份有限公司 Sustained local drug levels of innate immunity agonists
AU2020223441A1 (en) 2019-02-11 2021-07-29 Ascendis Pharma Growth Disorders A/S Dry pharmaceutical formulations of CNP conjugates
JP2022520189A (en) 2019-02-11 2022-03-29 アセンディス ファーマ ボーン ディジージズ エー／エス Liquid pharmaceutical formulation of PTH conjugate
US11458098B2 (en) 2019-04-29 2022-10-04 Insmed Incorporated Dry powder compositions of treprostinil prodrugs and methods of use thereof
US20220305136A1 (en) 2019-06-21 2022-09-29 Ascendis Pharma Oncology Division A/S Anti-ctla4 conjugates
EP3986478A1 (en) 2019-06-21 2022-04-27 Ascendis Pharma Oncology Division A/S Tyrosine kinase inhibitor conjugates
WO2020254612A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pd properties
WO2020254613A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Controlled-release tyrosine kinase inhibitor compounds with localized pk properties
WO2020254617A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pk properties
WO2020254607A1 (en) 2019-06-21 2020-12-24 Ascendis Pharma Oncology Division A/S Anti-ctla4 compounds with localized pd properties
JP2020011957A (en) * 2019-07-22 2020-01-23 コルセア ファーマ インコーポレイテッド Treprostinil derivative compound and method of using the same
JP2023510790A (en) 2020-01-13 2023-03-15 アセンディス ファーマ ボーン ディジージズ エー／エス Treatment of hypoparathyroidism
US20230241217A1 (en) 2020-05-04 2023-08-03 Ascendis Pharma A/S Hydrogel irradiation
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
CA3192772A1 (en) 2020-09-28 2022-03-31 Ascendis Pharma Bone Diseases A/S Improvement of physical and mental well-being of patients with hypoparathyroidism
JP7138685B2 (en) * 2020-10-26 2022-09-16 コルセア ファーマ インコーポレイテッド Treprostinil derivative compounds and methods of use thereof
WO2022194195A1 (en) * 2021-03-16 2022-09-22 江苏恒瑞医药股份有限公司 Treprostinil derivative and use thereof
CA3230895A1 (en) 2021-09-22 2023-03-30 Kennett Sprogoe Long-acting pth compound treatments
WO2023110758A1 (en) 2021-12-13 2023-06-22 Ascendis Pharma Growth Disorders A/S Effective doses of cnp conjugates
WO2023110727A2 (en) 2021-12-13 2023-06-22 Ascendis Pharma Oncology Division A/S Novel cancer treatments with tlr7/8 agonists
CN116444377A (en) * 2022-01-07 2023-07-18 广州楷石医药有限公司 Nitric oxide donor type treprostinil derivative, and pharmaceutical composition and application thereof
WO2023227505A1 (en) 2022-05-23 2023-11-30 Ascendis Pharma Growth Disorders A/S Liquid pharmaceutical formulations of cnp compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
CA1241324A (en) 1984-03-08 1988-08-30 Paul A. Aristoff Interphenylene carbacyclin derivatives
JP2003523935A (en) * 1999-03-31 2003-08-12 ユナイテッド セラピューティクス コーポレイション Prostaglandin compounds, compositions and methods for treating peripheral vascular disease and pulmonary hypertension
CA2843439A1 (en) * 2003-04-08 2004-10-21 Yeda Research And Development Co. Ltd Reversible pegylated drugs
US7199157B2 (en) * 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
EP1625856A1 (en) 2004-08-13 2006-02-15 Complex Biosystems GmbH Hydrogel polymeric conjugates of a prodrug
EP2120961A1 (en) * 2007-02-09 2009-11-25 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma
DK2369005T3 (en) * 2007-06-21 2013-06-24 Univ Muenchen Tech Biologically active proteins with increased stability in vivo and / or in vitro
MX344559B (en) 2008-04-29 2016-12-20 Ascendis Pharma As Pegylated recombinant human growth hormone compounds.
WO2010014258A2 (en) 2008-08-01 2010-02-04 Nektar Therapeutics Al, Corporation Conjugates having a releasable linkage
CA2732508C (en) * 2008-08-11 2016-03-15 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
CA2737040C (en) * 2008-09-19 2017-05-02 Nektar Therapeutics Polymer conjugates of therapeutic peptides
WO2010068754A2 (en) * 2008-12-10 2010-06-17 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of medicaments to the lungs
JP5839597B2 (en) 2009-06-08 2016-01-06 アムニクス オペレーティング インコーポレイテッド Glucose-regulating polypeptide and methods for making and using the same
AU2010277556B2 (en) * 2009-07-31 2014-10-09 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011042450A1 (en) * 2009-10-06 2011-04-14 Ascendis Pharma As Carrier linked paliperidone prodrugs
JP6092867B2 (en) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス Carrier-linked treprostinil prodrug

Also Published As

Publication number Publication date
US20190105400A1 (en) 2019-04-11
IL230712A0 (en) 2014-03-31
KR20140070545A (en) 2014-06-10
EP2741781A1 (en) 2014-06-18
KR101997939B1 (en) 2019-07-08
AU2012296954A1 (en) 2014-02-20
US10729778B2 (en) 2020-08-04
IL230712A (en) 2017-08-31
US9561287B2 (en) 2017-02-07
CA2843883C (en) 2020-04-28
WO2013024052A1 (en) 2013-02-21
MX349950B (en) 2017-08-22
MX2014001497A (en) 2014-04-25
US20140296150A1 (en) 2014-10-02
CN103857413A (en) 2014-06-11
CA2843883A1 (en) 2013-02-21
AU2012296954B2 (en) 2016-09-15
ZA201400977B (en) 2017-11-29
JP2014527050A (en) 2014-10-09
BR112014003225A2 (en) 2017-03-01
JP6092867B2 (en) 2017-03-08
HK1198359A1 (en) 2015-04-10

Similar Documents

Publication Publication Date Title
IN2014CN00989A (en)
PH12017501429A1 (en) Derivatives of betulin
WO2012122340A8 (en) Soluble guanylate cyclase activators
MY170713A (en) Treatment protocol of diabetes type 2
MX361653B (en) Process for preparing bile acid derivatives.
PH12014502733A1 (en) Neprilysin inhibitors
MD20150091A2 (en) Anti-viral compounds
MY187718A (en) Pharmaceutical formulations
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
MX2014004196A (en) Rasagiline citramide.
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
IN2012DN02139A (en)
TN2011000585A1 (en) Lxr modulators
TN2014000112A1 (en) Ep1 receptor ligands
MX349224B (en) Pharmaceutical composition for use in the treatment of a neurodegenerative disease.
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
MX2011011776A (en) Triptolide prodrugs.
WO2013093931A3 (en) Novel prodrugs of phenolic drugs
IN2014CN04449A (en)
WO2012104823A3 (en) Pyridopyrimidinone compounds in the treatment of neurodegenerative diseases
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
IN2013DN02555A (en)
MX2013012773A (en) Drug substances, pharmeceutical compositions and methods for preparing the same.
WO2014030173A3 (en) Improved process for preparation of atazanavir bisulfate
WO2012176163A3 (en) Compounds for the treatment of cancers associated with human papillomavirus